Suicidal behavior occurs in the context of a diathesis characterized by impairments in mood and emotion regulation, decision making, problem solving, and social appraisal.
1 Suicidal behavior is also associated with specific biomarkers,
2 mostly involving the serotonergic system and hypothalamic pituitary adrenal axis. We found individuals with major depressive disorder (MDD) who attempt suicide (attempters) have lower in vivo midbrain serotonin transporter binding compared with those who do not attempt suicide (nonattempters or control individuals),
3,4 suggesting that the differences in the proportions of suicide attempters studied may contribute to discrepant positron emission tomography (PET) findings in MDD.
5,6 Similarly, attempters with MDD showed lower serotonin transporter binding in the midbrain and pons
4 compared with controls. In contrast, a small study using iodine 123–labeled beta [3H]2-beta-carbomethoxy-3-beta-[4'-iodophenyl]tropane
7 single-photon emission computed tomography linked higher serotonin transporter binding in the globus pallidus to suicidal behavior. Using fluorodeoxyglucose F 18–labeled PET, a previous investigation
8 found attempters with MDD had lower regional rates of cerebral glucose metabolism in the right dorsolateral prefrontal cortex (PFC) compared with nonattempters with MDD, a discrepancy that roughly doubled after fenfluramine administration, which suggested impaired serotonergic response.
9 In a serotonin
2A binding study using
123I-5-I-R91150 and single-photon emission computed tomography, deliberate self-harming patients who did not use medication had less frontal serotonin
2A binding compared with controls. Thus, most studies implicate serotonergic dysfunction in suicidal behavior.